Bone & Joint Health References 27814

November 18, 2002

7 Min Read
Bone & Joint Health References


Bone & Joint Health References

  1. Berman, BM et al. "Use and referral patterns for 22 complementary and alternative medical therapies by members of the American College of Rheumatology." Arch Int Med. 162(7):766-70, 2002. http://archinte.ama-assn.org.

  2. Kurz B et al. "Dietary vitamins and selenium diminish the development of mechanically induced osteoarthritis and increase the expression of antioxidative enzymes in the knee joint of STR/1N mice." Osteoarthritis Cartilage. 10(2):119-26, 2002. www.harcourt-international.com/journals/joca.

  3. Clark AG et al. "The effects of ascorbic acid on cartilage metabolism in guinea pig articular cartilage explants." Matrix Biol. 21(2):175-84, 2002. www.elsevier.com/locate/matbio.

  4. McAlindon TE et al. "Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis?" Arthritis Rheum. 39(4):648-56, 1996. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746.

  5. Scherak O et al. "High dosage vitamin E therapy in patients with activated arthrosis." Z Rheumatol. 49(6):369-73, 1990.

  6. Brand C et al. "Vitamin E is ineffective for symptomatic relief of knee osteoarthritis: a six month double blind, randomized, placebo controlled study." Ann Rheum Dis. 60(10):946-9, 2001. http://ard.bmjjournals.com.

  7. Galleron S et al. "Reactive oxygen species induce apoptosis of synoviocytes in vitro. Alpha-tocopherol provides no protection." Cell Biol Int. 23(9):637-42, 1999. www.academicpress.com/cbi.

  8. De Roos AJ et al. "Serum carotenoids and radiographic knee osteoarthritis: the Johnston County Osteoarthritis Project." Public Health Nutr. 4(5):935-42, 2001. www.cabi-publishing.org/journals/phn.

  9. May SW. "Selenium-based pharmacological agents: an update." Expert Opin Investig Drugs. 11(9):1261-9, 2002. www.ashley-pub.com.

  10. McCarty MF, Russell AL. "Niacinamide therapy for osteoarthritis--does it inhibit nitric oxide synthase induction by interleukin-1 in chondrocytes?" Med Hypotheses. 53(4):350-60, 1999. www.harcourt-international.com/journals/mehy.

  11. Ekmekcioglu C et al. "Effect of sulfur baths on antioxidative defense systems, peroxide concentrations and lipid levels in patients with degenerative osteoarthritis." Forsch Komplementarmed Klass Naturheilkd. 9(4):216-20, 2002.

  12. Pavelka K et al. "Glucosamine sulfate use and delay of progression of knee osteoarthritis." Arch Int Med. 162(18):2113-23, 2002. http://archinte.ama-assn.org.

  13. Reginster JY et al. "Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial." Lancet. 357(9252):251-6, 2001. www.thelancet.com.

  14. Hughes R, Carr A. "A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee." Rheumatology. 41(3):279-284, 2002. http://rheumatology.oupjournals.org.

  15. Lippiello L et al. "In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate." Clin Orthop. 381:229-40, 2000. www.corronline.com.

  16. "Joint Remedies." Consum Rep. 67(1):18-21, 2002. www.consumerreports.org.

  17. Alekseeva LI et al. "[Pharmacoeconomic aspects of use of structum in osteoarthrosis.]" (Article in Russian.) Ter Arkh. 73(11):90-2, 2001.

  18. Uebelhart D et al. "Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study." Osteoarthritis Cartilage. 6(Suppl A):39-46, 1998. www.harcourt-international.com/journals/joca.

  19. Verbruggen G et al. "Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs." Clin Rheumatol. 21:231-43, 2002. http://link.springer.de/link/service/journals/10067.

  20. Lawrence R. "Methyl-Sulfonyl-Methane: A Double-blind Study of Its Use in Degenerative Arthritis." Am J Anti-Aging Med. 1:50, 1998.

  21. Ham KD et al. "Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys." Arthritis Rheum. 46(7):1956-64, 2002. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746.

  22. Rice MM et al. "Dietary soy isoflavone intake, postmenopausal estrogen use, and self-reported arthritis in older Japanese-American women." 4th International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, San Diego, Nov. 4-7, 2001. www.aocs.org/archives/soy.

  23. Kimmatkar N et al. "Effect of boswellia serrata in osteoarthritis of the knee: a double blind crossover study." Vitafoods, Geneva, May 13-15, 2002. www.vitafoods.co.uk.

  24. Altman RD, Marcussen KC. "Effects of a ginger extract on knee pain in patients with osteoarthritis." Arthritis Rheum. 44(11):2531-8, 2001. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746.

  25. Moskowitz RW. "Roll of collagen hydrolysate in bone and joint disease." Semin Arthritis Rheum. 30(2):87-99, 2000. www.harcourthealth.com/semarthrit.

  26. Trentham DE et al. "Use of undenatured type II collagen in the treatment of rheumatoid arthritis." Clin Pract Alt Med. 2(4):254-9, 2001.

  27. Barnett ML et al. "Treatment of rheumatoid arthritis with orally type II collagen. Results of a multicenter, double-blind, placebo-controlled trial." Arthritis Rheum. 41(2):290-7, 1998. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746.

  28. Toda Y et al. "Relationship between HLA-DRB1 genotypes and efficacy of oral type II collagen treatment using chicken cartilage soup in rheumatoid arthritis." Nihon Rinsho Meneki Gakkai Kaishi. 20(1):44-51, 1997.

  29. Barnett ML et al. "A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis." Arthritis Rhem. 39(4):623-8, 1996. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746.

  30. Cazzola M et al. "Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo-controlled study." Clin Exp Rheumatol. 18(5):571-7, 2000. www.clinexprheumatol.org.

  31. Hughes DA, Pinder AC. "n-3 polyunsaturated fatty acids inhibit the antigen-presenting function of human monocytes." Am J Clin Nutr. 71(1 Suppl):357S-60S, 2000. www.ajcn.org.

  32. Curtis CL et al. "n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation." J Biol Chem. 275(2):721-4, 2000. www.jbc.org.

  33. Volker DH et al. "The eicosapentaenoic to docosahexaenoic acid ratio of diets affects the pathogenesis of arthritis in Lew/SSN rats." J Nutr. 130(3):559-65, 2000. www.nutrition.org.

  34. Ergas D et al. "n-3 fatty acids and the immune system in autoimmunity." Isr Med Assoc J. 4(1):34-8, 2002. www.ima.org.il/imaj.

  35. Calder PC. "Dietary modification of inflammation with lipids." Proc Nutr Soc. 61(3):345-58, 2002. www.cabi-publishing.org/journals/pns.

  36. Furse RK et al. "Oral administration of gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, modulates interleukin-1beta production by human monocytes." J Clin Immunol. 22(2):83-91, 2002. www.kluweronline.com/issn/0271-9142/current.

  37. De Bandt M et al. "Vitamin E uncouples joint destruction and clinical inflammation in a transgenic mouse model of rheumatoid arthritis." Arthritis Rheum. 46(2):522-32, 2002. www3.interscience.wiley.com/cgi-bin/currentissue?ID=76509746.

  38. Helmy M et al. "Antioxidants as adjuvant therapy in rheumatoid disease. A preliminary study." Arzneimittelforschung. 51(4):293-8, 2001.

  39. Spiller G et al. American College of Nutrition scientific meeting, San Antonio, Texas, Oct. 4, 2002.

  40. Jain NK et al. "Antinociceptive and Anti-inflammatory effects of tanacetum parthenium L. extract in mice and rats." J Ethnopharmacol. 68(1-3):251-9, 1999. www.elsevier.nl/inca/publications/store/5/0/6/0/3/5.

  41. Williams CA et al. "The flavonoids of tanacetum parthenium and T. vulgare and their anti-inflammatory properties." Phytochemistry. 51(3):417-23, 1999. www.elsevier.com/locate/issn/00319422.

  42. Kwok BH et al. "The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase." Chem Biol. 8(8):759-66, 2001. www.elsevier.com/gej-ng/10/14/33/show.

  43. Sander O et al. "Is H15 (resin extract of Boswellia serrata, "incense") a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study." Z Rheumatol. 57(1):11-6, 1998.

  44. Allen M et al. "Elk velvet antler in rheumatoid arthritis: phase II trial." Biol Res Nurs. 3(3):111-8, 2002. www.sagepub.co.uk/journals/details/j0282.html.

  45. Bierer TL, Bui LM. "Improvement of arthritis signs in dogs fed green-lipped mussel (Perna canaliculus)." J Nutr. 132(6 Suppl 2):1634S-6S, 2002. www.nutrition.org.

  46. Dawson-Hughes B. "Calcium Supplementation and Bone Loss: A Review of Controlled Clinical Trials." Am J Clin Nutr. 54(1):274S-80S, 1991. www.ajcn.org.

  47. Civitelli R et al. "Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy." Arch Int Med. 162(12):1409-15, 2002. http://archinte.ama-assn.org.

  48. Jensen C et al. "Long-term effects of nutrient intervention on markers of bone remodeling and calciotropic hormones in late-postmenopausal women." Am J Clin Nutr. 75(6):1114-20, 2002. www.ajcn.org.

  49. Barnes S. "Evolution of the health benefits of soy isoflavones." Proc Soc Exp Biol Med. 217:386-398, 1998. www.ebmonline.org.

  50. Kritz-Silverstein D, Goodman-Gruen DL. "Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women." J Womens Health Gend Based Med. 11(1):69-78, 2002. www.liebertpub.com/JWH/default1.asp.

  51. Potter SM et al. "Soy protein and isoflavones: their effects on blood lipoids and bone density in postmenopausal women." Am J Clin Nutr. 68(6 Suppl):1375S-1379S, 1998. www.ajcn.org.

  52. Alekel DL et al. "Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women." Am J Clin Nutr. 72(3):844-52, 2000. www.ajcn.org.

  53. Anderson JJB et al. "Soy isoflavones: no effects on bone mineral content and bone mineral density in healthy, menstruating young adult women after one year." J Am Coll Nutr. 21(5):388-93, 2002. www.am-coll-nutr.org/jacn/jacn.htm.

  54. Halpner AD et al. "The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women." J Womens Health Gend Based Med. 9(9):995-8, 2000. www.liebertpub.com/JWH/default1.asp.

  55. Ohta H et al. "Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass." Horm Res. 51(4):178-83, 1999. www.karger.com/journals/hre/hre_jh.htm.

  56. Alexandersen P et al. "Ipriflavone in the Treatment of Postmenopausal Osteoporosis, A Randomized Controlled Trial." JAMA. 285:1482-1488, 2001. www.jama.com.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like